CHEK2 Gene Mutation Screening Guidelines
CHEK2 genetic testing should be offered to adults with personal or family history of early-onset breast cancer (particularly before age 50), colorectal cancer, prostate cancer, or thyroid cancer, especially when multigene panel testing is being performed for hereditary cancer evaluation. 1
Who Should Be Tested
Primary Indications for CHEK2 Testing
Breast Cancer Context:
- Women with breast cancer diagnosed before age 50
- Individuals with bilateral breast cancer
- Patients with breast cancer and a family history of breast cancer on either maternal or paternal side
- Young patients (under 30) with breast cancer warrant broader panel testing that includes CHEK2 1
Other Cancer Types: When CHEK2 pathogenic variants are identified through tumor testing in the following cancers, germline confirmation should be offered 1:
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Thyroid cancer
Family History Triggers:
- Two or more first- or second-degree relatives with breast cancer
- Family history of early-onset cancers (before age 50)
- Multiple cancer types in the family including breast, colorectal, prostate, or thyroid cancers [@1-8@]
Testing Approach
When to Include CHEK2 in Genetic Testing
Multigene panel testing is the preferred approach rather than testing CHEK2 in isolation. CHEK2 should be included when:
- Performing hereditary breast and ovarian cancer syndrome evaluation
- BRCA1/2 testing is negative but clinical suspicion remains
- Tumor sequencing identifies a CHEK2 variant (requires germline confirmation) 2
Important caveat: CHEK2 is NOT currently included on the ACMG Secondary Findings list for incidental reporting during exome/genome sequencing, largely because management strategies require relevant family history context 2
Variant-Specific Considerations
Truncating vs. Missense Variants
Truncating variants (e.g., c.1100del, c.1434del):
- Confer higher breast cancer risk (OR ~8.19)
- Warrant more intensive surveillance
- Earlier age of breast cancer onset (average 44.4 years) 3
Missense variants:
- Generally lower penetrance than truncating variants
- Some exceptions exist (e.g., p.Arg117Gly may have higher risk)
- Many missense variants like p.I157T (c.470T>C) and p.S428F (c.1283C>T) are low-penetrant with relative risk of only 1.5 and do NOT warrant the same screening recommendations as truncating variants 1
- Functional analysis may be needed to determine clinical significance 3
Critical pitfall: Not all CHEK2 variants carry the same risk. Avoid treating all CHEK2 variants equally—variant type matters significantly for risk stratification and management decisions 2, 1.
Family Testing Cascade
Who in the Family Should Be Tested
Once a CHEK2 pathogenic variant is identified in a proband:
High priority for testing:
- All first-degree relatives (siblings, parents, children)
- Sisters of female probands (breast cancer risk)
- Brothers if family history includes prostate cancer [@1-8@]
Important consideration: CHEK2 variants can be inherited from the side of the family WITHOUT cancer history, so both maternal and paternal lineages should be considered 2
Risk Assessment Framework
Personalized Risk Calculation
Risk assessment should use CanRisk or similar validated models that incorporate:
- Specific CHEK2 variant type
- Family history (both sides)
- Traditional breast cancer risk factors
- Age at diagnosis in affected relatives [@1-8@]
Key point: Family history significantly modifies risk in CHEK2 carriers. A carrier with strong family history may have >30% lifetime breast cancer risk, while a carrier without family history has substantially lower risk 2.
Genetic Counseling Requirements
Pre- and post-test genetic counseling is essential because:
- Risk estimates for CHEK2 are evolving and variant-specific
- Management recommendations differ by country and healthcare system
- Negative predictive testing in families does NOT reduce risk to population level (unlike high-penetrance genes like BRCA1/2)
- Residual risk calculations are needed for family members who test negative 2
Population-Specific Considerations
Founder variants vary by ancestry:
- c.1100del is common in European populations 4
- Different variants predominate in other populations (e.g., c.846+1G>C, c.349A>G in Brazilian populations) 5
- Intronic variants may have uncertain risk estimates in non-European populations 6
Clinical implication: Risk data derived primarily from European populations may not directly apply to other ancestries, requiring cautious interpretation 6.
Practical Testing Scenarios
When Tumor Testing Identifies CHEK2
If tumor sequencing reveals a CHEK2 variant:
- Germline confirmation is mandatory—tumor variants can be somatic
- Common variants like c.1100del found in tumors can be presumed germline but still require confirmation
- Insurance may initially deny germline testing if tumor testing was already performed; advocate for coverage 2
Testing in Young Patients
Patients diagnosed with breast cancer before age 30 warrant comprehensive panel testing including CHEK2, even without strong family history 1.
What NOT to Screen For
CHEK2 testing is NOT indicated for:
- Ovarian cancer risk assessment (no established association) 2
- Population screening in asymptomatic individuals without personal or family cancer history
- Routine inclusion in all cancer genetic testing panels without appropriate clinical context
[@1-16@]